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1. Introduction
Lysosomes are organella involving the catabolism of biomolecules extracellularly and intra‐
cellularly incorporated, which contain more than 60 distinct acidic hydrolases (lysosomal
enzymes) and their co-factors. Lysosomal storage diseases (LSDs) are caused by germ-line
gene mutations encoding lysosomal enzymes, their activator proteins, integral membrane
proteins, cholesterol transporters and proteins concerning intracellular trafficking of lysoso‐
mal enzymes [1,2]. The LSDs associate with excessive accumulation of natural substrates, in‐
cluding glycoconjugates (glycosphingolipids, oligosaccharides derived from glycoproteins,
and glycosaminoglycans from proteoglycans) as well as heterogeneous manifestations in
both visceral and nervous systems [1,2]. LSDs comprise greater than 40 diseases, of which
incidence is about 1 per 100 thousand births, and recognized as so-called ‘Orphan diseases’.
In the biosynthesis of lysosomal matrix enzymes, newly synthesized enzymes are N-glyco‐
sylated in the endoplasmic reticulum (ER) and then phosphorylated in the Golgi apparatus
on the 6 position of the terminal mannose residues (M6P) via two step reactions catalyzed
by Golgi-localized phosphotransferase and uncovering enzyme necessary to expose the ter‐
minal M6P residues [3,4]. The M6P-carrying enzymes then bind the cation-dependent man‐
nose 6-phosphate receptor (CD-M6PR) at physiological pH in the Golgi. The enzyme–
receptor complex is then transported to late-endosomes where the M6P-carrying enzymes
dissociate from the receptor at acidic pH, while the CD-M6PR then traffics back to the Golgi
as a shuttle. M6P-carrying enzymes are delivered to lysosomes via fusion with late-endo‐
somes. A small percentage of lysosomal enzymes is known secreted from the cell. The se‐
creted M6P-carrying enzymes or the dephosphorylated enzyme with terminal mannose
residues can then bind either cation-independent M6P/IGFII receptor (CI-M6PR) or man‐
nose receptor (MR) on the plasma membrane [4,5]. Thus, the extracellular lysosomal en‐
zymes can be endocytosed via both glycan receptors to be delivered to the lysosomes where
the captured enzymes can exhibit their normal catabolic functions.
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Many therapeutic approaches developed for LSDs, including bone marrow transplantation
(BMT), stem cell-based therapy (SCT), enzyme replacement therapy (ERT) and ex vivo gene
therapy, are based on this physiologic secretion/uptake system (cross-correction). In success‐
ful intravenous ERT for LSDs involving mainly visceral symptoms, including type 1 Gauch‐
er disease [6,7] and mucopolysaccharidosis I (MPS I) [8], MPS VI [9], Fabry [10,11], and
Pompe diseases [12,13], either MR or CI-M6PR have been utilized as delivery targets of the
recombinant lysosomal enzyme drugs produced by mammalian cell lines including CHO
cells and human fibrosarcoma cells. However, intravenous ERT has several disadvantages:
i) long-life therapy, ii) requirement of large amounts of recombinant human enzymes, iii)
high cost, iv) immune response to the exogenous enzymes [14], and v) ineffectiveness to‐
wards LSDs involving neurological signs because of the blood–brain barrier (BBB), although
clinical trials are under-going of intrathecal ERT for MPS type I [15], II and IIIB patients. SCT
using hematopoietic stem cell (HSC), hematopoietic precursor cell (HPC) and mesenchymal
stem cell (MSC) derived from bone marrows has also been utilized as a treatment for LSDs
animal models and patients [16-20]. BMT and SCT are based on that stem cells distribute
widely in vivo as sources continuously producing the deficient enzymes. However, applica‐
tion of BMT is generally limited to LSDs that show a clear beneficial response and for which
ERT is not available.
On the other hand, the gene replacement therapy (GT) [21-24] has advantages, including i)
long-lasting therapy by a single transduction utilizing recombinant viral gene transfer vec‐
tors [25-29], ii) cross-correction effects, and iii) possible CNS-directed application to LSDs in‐
volving neurological symptoms [23,24,30-33], whereas GT has disadvantages, including i)
low levels and persistence of expression in all tissues of patients, ii) incomplete response to
therapy dependent on clinical phenotypes, and iii) insertional mutagenesis resulting in neo‐
plasia. GT is one of the promising therapeutic approaches, especially toward LSDs involving
CNS symptoms. In this review, we focus on the challenges to develop the CNS-directed GT
for LSDs including GM2 gangliosidoses.
2. GM2 gangliosidoses
Lysosomal β-hexosaminidase (Hex, EC 3.2.1.52) is a glycosidase that catalyzes the hydroly‐
sis of terminal N-acetylhexosamine residues at the non-reducing ends of oligosaccharides of
glycoconjugates [34,35]. There are two major Hex isozymes in mammals including man,
HexA (αβ, a heterodimer of α- and β-subunits) and HexB (ββ, a homodimer of β-subunit),
and a minor unstable isozyme, HexS (αα, a homodimer of α-subunit). All these Hex iso‐
zymes can degrade terminal β-1,4 linked N-acetylglucosamine (GlcNAc) and N-acetylgalac‐
tosamine (GalNAc) residues, while only HexA and HexS prefer negatively charged
substrates and cleave off the terminal N-acetylglucosamine 6-sulfate residues in keratan sul‐
fate. Hex A is essential for cleavage of the GalNAc residue from GM2 ganglioside (GM2) in
co-operation with GM2 activator protein (GM2A) [34,35].
Tay-Sachs disease (TSD) (MIM 272800) and Sandhoff disease (SD) (MIM 268800) are autoso‐
mal recessive GM2 gangliosidoses caused by germ-line mutations of HEXA (locus 15q23-24)
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encoding the Hex α-subunit, and HEXB (locus 5q13) encoding the Hex β-subunit, respec‐
tively [34,35]. The genes exhibit sequence homology, and the gene products exhibit 57% sim‐
ilarity in amino acid sequence. In TSD, the genetic defect of HEXA causes a deficiency of
HexA (αβ with excessive accumulation of GM2 in the central nervous system (CNS), result‐
ing in neurological disorders, including weakness, startle reaction, early blindness, progres‐
sive cerebellar ataxia, psychomotor retardation, and cherry red spots, and macrocephaly. In
SD, the inherited defect of HEXB leads to simultaneous deficiencies of HexA and HexB with
accumulation of GM2 in the CNS and of oligosaccharides carrying the terminal N-acetylhex‐
osaminyl residues at their non-reducing ends, resulting in involvement of the visceral or‐
gans including cardiomegaly and minimal hepatosplenomegaly as well as the neurological
symptoms. GM2 gangliosidosis AB variant (MIM 272750) is very rare autosomal recessive
LSD caused by the gene mutation of GM2 activator protein (GM2A locus 5q31.3-q33.1)
[34,36]. The gene product GM2A specifically binds GM2 to pull up from membranes in lyso‐
somes, and present it to HexA for degradation of GM2. The deficiency of GM2A also cause
the GM2 accumulation and neurological symptoms similar to those of TSD and SD [34,36].
The pathogenic mechanisms of these GM2 ganliosidoses has not been fully elucidated, al‐
though neurodegeneration and neuroinflammation have been reported to contribute to the
pathogenesis [34,35,37,38].
GM2 gangliosidoses including TSD and SD exhibit a spectrum of clinical phenotypes, which
vary from the severe infantile form (classical type), which is of early onset and fatal culmi‐
nating in death before the age of 4 years, to the late-onset and less severe form (atypical
type), which allows survival into childhood (subacute form) or adulthood (chronic form)
[34,35,37,38]. Many mutations have been identified for each gene, including missense, dele‐
tion and insertion mutations [34,39-41]. Structural information on the basis of the crystal
structures of human Hex B [42,43] and HexA [44] allowed us to predict the effects of mis‐
sense mutaitons identified in TSD [34,39,40] and SD [34,39,41] on the protein structures of
mutated gene products. According to these reports, the β-subunit of Hex comprises two do‐
mains (domain I and II). Domain I has an α/β topology, and domain II is folded into a (β/α)8-
barrel with the active site pocket at the C-termini of the β-strands. An extrahelix that follows
the eighth helix of the (β/α)8-barrel is located between domain I and the barrel structure. On‐
ly the α-subunit active site can hydrolyze GM2 due to a flexible loop structure that is re‐
moved post-translationally from β, and to the presence of αN423 and αR424. The loop
structure is involved in binding the GM2A, while αR424 is critical for binding the carboxy‐
late group of the N-acetylneuraminic acid residue of GM2. The β-subunit lacks these key
residues and has βD452 and βL453 in their place. The β-subunit therefore cleaves only neu‐
tral substrates efficiently. The representative amino acid substitutions have been reported in
the α-subunit, including R170W, R178H, W420C, C458Y, L484P, R499C/H, and R504C/H, as
well as in the β-subunit, R505Q and C534Y. The dysfunctional and destabilizing defects in
Hex α- and β-subunits well reflect biochemical and phenotypic abnormalities in TSD and
SD, respectively. Such structural information should be useful to develop novel therapeutic
approaches for these disorders [34,45].
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3. General aspects of gene therapy for LSDs
Gene therapy (GT) utilizing various vectors for gene transfer has been preclinically and
clinically  applied  for  LSDs  in  recent  years  [21-33].  Recombinant  viral  vectors  including
retroviruses [25,32],  adenovirus [26-28],  herpes simplex virus (HSV) [33],  adeno-associat‐
ed  virus  (AAV)  [29,46-48]  and lentiviruses  [24,49-51]  are  utilized currently  as  the  effec‐
tive  means  of  gene  transfer  and  enzyme  expression.  The  retroviruses  have  been  used
primarily in ex vivo  applications to transduce the dividing cells,  such as HPC, HSC and
other  stem cells  in  culture,  which  are  then  transplanted  into  a  recipient.  However,  the
retroviral vectors are not suitable for in vivo  GT due to lack of ability to transduce non-
dividing cells. On the other hand, the adenoviruses can infect very efficiently non-divid‐
ing cells.  However,  the  use  of  the  early  generation adenoviral  vectors  has  been limited
due  to  their  strong  antigenicity.  In  contrast,  lentiviruses  can  infect  both  dividing  and
non-dividing cells,  and are  applicable  to  both ex  vivo  and in  vivo  GT.  AAV vectors  are
able to transduce many cell  types in vivo  effectively,  and it  is  often used as a safer tool
for gene transfer because of the lower immunogenicity.
The application of recombinant viral vectors varies dependently on several factors, includ‐
ing ease of vector delivery, expression level in cell types and target tissues and organs main‐
ly affected with LSD. At initial stage of development of GT for LSDs, the ex vivo
transduction of HPC derived from type 1 Gaucher disease [25] and fibroblasts obtained
from MPS VII model mice [32] using retroviral vectors was successful to secrete high levels
of the enzymes and corrected the deficiencies. The ex vivo GT using retroviral vector and au‐
tologous HSC or HPC (human CD34+ cells) derived from bone marrow of the patient as do‐
nor cells for transplantation was clinically applied to type 1 Gaucher disease patients, and
demonstrated the production of therapeutically effective levels of enzyme activity, resulting
in persistent circulating enzyme available to tissues and organs [52]. The transduced cells al‐
so migrated into many tissues, expressed high levels of enzyme and reduced lysosomal stor‐
age in several critical tissues. However, several problems had been emerged, including less
efficiency in transduction of human HSC or HPC using murine-based retroviral vector and
difficulty in continuous production of sufficient amounts of recombinant enzymes to main‐
tain the effectiveness.
The lentiviral vector based on human immunodeficiency virus had been expected to over‐
come the limitation of early generation of murine-based retroviral vectors in ex vivo GT [53].
Transduction efficiency of human HPC derived from Gaucher disease patient [54] was im‐
proved by using HIV-based lentiviral vector. β-Glucuronidase (GUSB)-deficient mobilized
peripheral blood CD34(+) cells from a patient with MPSVII were transduced with a third-
generation lentiviral vector encoding human GUSB, and then xenotransplantation to murine
model with MPSVII. The corrected cells distributed widely throughout recipient tissues, re‐
sulting in significant therapeutic effects including improvements in biochemical parameters
and reduction of the lysosomal distension of several host tissues [24].
Direct in vivo GT using adenoviral vector have been preclinically applied to murine mod‐
els  with Pompe,  Fabry,  and Wolman diseases,  resulted in sufficient  expression of  circu‐
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lating  enzymes  and  reduction  of  storage  materials  in  the  affected  tissues  [27,55,  56].
However,  these  therapeutic  effects  were  transient  because  of  the  severe  immune  reac‐
tions directed against the adenoviral vector. Single intravenous administration of a modi‐
fied  adenoviral  vector  to  Pompe  disease  mice  was  demonstrated  to  reduce  glycogen
storage with minimal immune response [57].
The AAV vector has been also developed as an alternative gene transfer tool for direct in
vivo GT for LSDs. Intramuscular injection of AAV2 serotype vector [58,] in the murine mod‐
els of Pompe disease, Fabry disease and MPS VII caused high level expression in the muscle
tissues but lower levels of circulating enzyme activity [59-61], although the efficacy varied
depending on the diseases. Intravenous injection of AAV2 vectors in young adult mice with
MPS VII and Fabry disease reduced the lysosomal storage in many tissues [61,62] Significant
improvement was observed in MPS VII and MPS I mice following intravenous delivery of
AAV2 vector during the neonatal period [28,63]. These findings suggested the effectiveness
of AAV vector delivery at early presymptomatic stage to prevent onset rather than delayed
intervention for progressive LSDs.
As mentioned above, GT has therapeutic potency for LSDs involving neurological symp‐
toms superior to that of clinically applied intravenous ERT, in which the enzyme cannot
cross the BBB. Several CNS-directed ex vivo and in vivo GT have been performed for animal
models of LSDs with brain involvement. Genetically modified bone marrow stromal cells
using retroviral vector improved CNS pathology and cognitive function in MPS VII and
GM1-gangliosidosis mice following intraventricular transplantation [64, 65]. Genetically
modified human neuronal precursor cells (NPCs) differentiated into neurons and astrocytes
and expressed β-glucuronidase for at least 6 months after injection into striata of adult MPS
VII model mice. However, the cells did not migrate and correction was limited to regions
adjacent to the transplantation site [66] In vivo GT of metachromatic leukodystrophy (MLD)
by lentiviral vector corrected neuropathology and protected against learning impairments in
the model mice [49]. CNS-directed in vivo GT using AAV vectors have been demonstrated
to have therapeutic effects on the mouse model of LSDs involving neurological signs, in‐
cluding MPS IIIB [67], MPS VII [68], Globoid cell leukodystrophy (GLD) [69], Nieman-Pick
A (NPA)[70] and α-mannosidosis [71] by intracranial administration of recombinant AAV
vectors. Thus, AAV vectors exhibit a number of properties that have made this vector sys‐
tem an excellent choice for both CNS gene therapy and basic neurobiological investigations.
In vivo, the preponderance of AAV vector transduction occurs in neurons where it is possi‐
ble to obtain long-term, stable gene expression with very little accompanying toxicity. Pro‐
moter selection, however, significantly influences the pattern and longevity of neuronal
transduction distinct from the tropism inherent to AAV vectors. AAV vectors have success‐
fully manipulated CNS function using a wide variety of approaches including expression of
foreign genes, expression of endogenous genes, expression of antisense RNA and expression
of RNAi. With the discovery and characterization of different AAV serotypes, as well as the
creation of novel chimeric serotypes, the potential patterns of in vivo vector transduction
have been expanded substantially, offering alternatives to the more studied AAV 2 serotype.
Furthermore, the development of specific AAV chimeras offers the potential to further re‐
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fine targeting strategies. These different AAV serotypes also provide a solution to the im‐
mune silencing that proves to be a realistic likelihood given broad exposure of the human
population to the AAV 2 serotype. These advantageous CNS properties of AAV vectors
have fostered a wide range of clinically relevant applications including Parkinson's disease,
lysosomal storage diseases, Canavan's disease, epilepsy, Huntington's disease and ALS. In
many cases the proposed therapies have progressed to phase I/II clinical trials. Each individ‐
ual application, however, presents a unique set of challenges that must be solved in order to
attain clinically effective gene therapies [72].
4. Gene therapy for GM2 gangliosidoses
4.1. Experimental and preclinical gene therapy using animal models
GM2 gangliosidoses, including Tay-Sachs disease (TSD), Sandhoff disease (SD) and the AB
variant disorder, are characterized by excessive accumulation of GM2 and neurological
symptoms due to progressive neurodegeneration and gliosis, as described above. However,
there is no effective therapy for GM2 gangliosidoses at present, although we have reported
and proposed the clinical potential of the intrathecal ERT using recombinant modified hu‐
man HexA [73] and HexB [74,75] in recent years. It is crucial for treatment of GM2 ganglio‐
sidoses to develop the CNS-directed molecular therapy including such intrathecal ERT, ex
vivo and in vivo GT or the combined methods including SRT [76]. In this chapter, we would
focus on the CNS-directed GT and summarize the preclinical approaches using small and
large animal models with GM2 gangliosidoses.
At early stage of development of GT for GM2 gangliosidoses, gene transduction of cultured
cells was performed by utilizing recombinant vectors (virus or plasmids), and examined the
effect of cross correction due to the secreted Hex isozymes. Guidotti, JE. et al. constructed a
retroviral vector encoding for the α-subunit of human HexA (HEXA cDNA) and transduced
the HexA-deficient fibroblasts derived from Tay-Sach disease model mice (Hexa-/- mice) [77].
Transduced cells overexpressed the human Hex α-subunit to produce the chimeric HexA
composed of human α-subunit and murine β-subunit, which were taken up via CI-M6PR by
non-transduced cells and exhibited the cross-correction effect.
On the other hand, Martino et al. also constructed a retroviral vector encoding for the α-sub‐
unit of human HexA (HEXA cDNA) and transduced NIH3T3 murine fibroblasts, resulting
in production of large amount of human Hex activity. The secreted Hex was incorporated
into the fibroblasts derived from TSD patient, but failed to correct intracellular GM2 storage,
probably because of the absence of HexA isozyme sufficient for degrading the accumulated
GM2 [78]. Akli S et al. produced a replication-deficient recombinant adenovirus (AdRSV)
coding the human HEXA cDNA, and transduced the fibroblasts derived from TSD patients.
Transdused cells restored the Hex activity ranging from 40 to 84% of the normal, and secret‐
ed the Hex a-subunit, which were delivered to lysosomes and degraded the GM2 accumu‐
lated in TSD fibroblasts [79].
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We transfected an expression vector plasmid coding the human HEXB cDNA to fibroblasts
derived from Sandhoff disease mice (Hexb-/- mice) and established a transformed murine cell
line stably producing the human Hex β-subunit [80]. However, the GM2 accumulated in the
transformed murine cell line was not reduced, while co-transfection of the human HEXA
cDNA resulted in restoration of HexA activity and reduction of GM2 storage.
Yamaguchi et al. evaluated the systemic in vivo GT for Hexb-/- mice using cationic liposome-
mediated plasmid using the Hexb-/- mice [81]. The mice received a single intravenous injec‐
tion of two plasmids, encoding the human α and β subunits of hexosaminidase cDNAs. As a
result, 10–35% of normal levels of Hex expression, theoretically therapeutic levels, were ach‐
ieved in most visceral organs, but not in the brain, 3 days after injection with decreased lev‐
els by day 7. Histochemical staining confirmed widespread enzyme activity in visceral
organs. Both GA2 and GM2 were reduced by almost 10% and 50%, respectively, on day 3,
and by 60% and 70% on day 7 compared with untreated age-matched Hexb-/- mice.
These findings suggested that brain-directed in vivo GT based on direct transduction of the
affected tissues by single gene transfer or ex vivo GT utilizing double genes (i.e. HEXA and
HEXB cDNAs) for producing the homo-specific HexA should be required to achieve the
therapeutic effects on TSD and SD. Since then, studies on the CNS-directed in vivo GT and ex
vivo GT have been performed as two streams of development of molecular therapy for GM2
gangliosidoses.
4.2. CNS-directed in vivo gene therapy
Bourgoin et al. constructed the recombinant adenovirus coding the human HEXB cDNA,
and transduced the fibroblasts derived from patient with SD resulting in high expression of
HexA and HexB activities. They also administered the adenoviral vector intracerebrally to
SD mice (Hexb-/- mice), and succeeded in expression of near-normal level of enzymatic ac‐
tivity in the entire brain. Co-injection of hyperosmotic concentrations of mannitol with low
doses of the adenoviral vector enhanced the vector diffusion in the injected hemisphere
without viral cytotoxicity. It was suggested that such combination will allow a high and dif‐
fuse transduction efficiency of adeno-viral vector in the brain with higher safety [82].
Martino et al. also constructed a non-replicating herpes simplex viral (HSV) vector encoding
Hexa cDNA. They transplanted the encapsuled recombinant HSV into the brain of Hexa-/-
mice. The diffusion of recombinant HSV and the secreted HexA derived from transduced
neural cells corrected the GM2 storage in the brain during one month due to cross correction
effects without adverse effects due to the viral vector [83].
Caillaud and co-workers reported that mono and bicistronic lentiviral vectors based on a
simian immunodeficiency virus (SIV) containing the human HEXA or/and HEXB cDNAs
were constructed and tested on the fibroblasts derived from the SD patient [84]. The bicis‐
tronic SIV.ASB vector encoding both HEXA and HEXB cDNAs enabled a massive restora‐
tion of Hex activity. A large reduction of GM2 accumulation in SIV.ASB transduced cells.
Moreover, the Hex isozymes secreted by transduced SD fibroblasts were endocytosed in de‐
ficient cells via CI-M6PR, allowing GM2 metabolism restoration in cross-corrected cells.
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Therefore, the bicistronic lentivector supplying both HexA and HexB isozymes may provide
a potential therapeutic tool for the treatment of TSD and SD. A mechanistic link was demon‐
strated among GM2 accumulation, neuronal cell death, reduction of sarcoplasmic/endoplas‐
mic reticulum Ca2+-ATPase (SERCA) activity, and axonal outgrowth. Arfi et al. examined the
ability of the SIV.ASB vector to reverse these pathophysiological events, hippocampal neu‐
rons derived from embryonic Hexb-/- mice, which were transduced with the lentival vector
[85]. Normal axonal growth rates, the rate of Ca2+ uptake via the sarcoplasmic/endoplasmic
reticulum Ca2+-ATPase (SERCA) activity and the sensitivity of the neurons to thapsigargin-
induced cell death were restored concomitantly with a decrease in GM2 and GA2 levels.
Thus, the bicistronic SIV.ASB vector was revealed to reverse the biochemical defects and
down-stream consequences in SD neurons, suggesting its potential of systemic and CNS-di‐
rected in vivo GT. Kyrkanides S. et al. performed the system in vivo GT utilizing the re‐
combinant lentiviral vector FIV coding human HEXB cDNA to the neonatal Hexb-/- mice via
intrapenitoneal administration. They also demonstrated the distribution of Hex isozymes in‐
to the CNS, including periventricular areas of the cerebrum as well as in the cerebellar cor‐
tex, and reduction of GM2 accumulated in these areas [86].
Cachon-Gonzalez et al. has reported that the Hexb-/- mice treated by stereotaxic intracranial
inoculation of recombinant adeno-associated viral (rAAV) vectors encoding the human
HEXA and HEXB cDNAs, including an HIV tat sequence as a protein transduction domain
(PTD), to enhance protein expression and distribution [87]. Hexb-/- mice survived for >1 year
with sustained, widespread and abundant enzyme delivery in the CNS. Onset of the disease
was delayed with preservation of motor function; inflammation and GM2 storage in the
brain and spinal cord was reduced. Gene delivery of the human HexA (αβ) by using AAV
vectors has realistic potential for treating the TS and SD patients. Sargeant TJ. et al. demon‐
strated that intracranial co -injection of rAAV serotype 2/1 (rAAV2/1) vectors encoding the
human HEXA and HEXB cDNAs prevents neuronal loss in the Hexb-/- mice brain tissues, in‐
cluding thalamus, brainstem and spinal cord, and correlated with increased lifespan [88].
Moreover, they performed intracranial co-injection of rAAV2/1 vectors into 1-month-old
Hexb-/- mice [89]. As a result, the treated mice gave unprecedented survival to 2 years and
prevented disease throughout the brain and spinal cord. Classical manifestations of disease,
including spasticity were resolved by localized gene transfer to the striatum or cerebellum,
respectively. Abundant biosynthesis of Hex isozymes and their global distribution via axo‐
nal, perivascular, and cerebrospinal fluid (CSF) spaces, as well as diffusion, account for the
sustained phenotypic rescue—long-term protein expression by transduced brain parenchy‐
ma, choroid plexus epithelium, and dorsal root ganglia neurons supplies the corrective en‐
zyme. Prolonged survival permitted expression of cryptic disease in organs not accessed by
intracranial vector delivery.
4.3. CNS-directed ex vivo gene therapy
Ex vivo GT for GM2 gangliosidoses is based on the results of BMT previously reported
[90,91]. BMT was demonstrated to prolong life span and ameliorate neurological symptoms
in Hexb-/- mice [90], and the synergistic effects was also shown in combination with substrate
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reduction therapy (SRT) utilizing deoxynojirimycin derivatives [91]. Transduction of neural
cells derived from Hexa-/- and Hexb-/- mice by recombinant viral vectors was performed.
Lacorazza HD et al. constructed the ecotropic retrovirus encoding the human HEXA cDNA
and transduced multipotent neural progenitor cell lines, which stably expressed and secret‐
ed high levels of active HexA and cross-corrected the metabolic defect including GM2 stor‐
age in TSD fibroblastic cell line. The genetically engineered CNS progenitors were
transplanted into the brains of both normal fetal and neonatal mice, in which substantial
amounts of human Hex α-subunit and activity were observed throughout the brain enough
for therapeutic effect in TSD [92].
Tsuji D. et al. constructed a recombinant lentiviral vector encoding the murine Hexb cDNA,
and transduced microglial cells established from the brains of Hexb-/- mice [50]. Transduced
microglial cells produced and secreted Hex activity, in which the intracellularly accumulat‐
ed GM2 and oligosaccharides with terminal N-acetylglucosamine residues were reduced.
Transduced microglial cell line was expected as a donor for brain-directed ex vivo GT.
Mesenchymal stem cells (MSCs) derived from bone marrow stromal cells are one of the can‐
didates for autologous donor cells for ex vivo GT, and have the multipotency to differentiate
under specific culture conditions into other cell types such as osteoblasts, adipocytes, and
chondrocytes [93,] as well as into neural lineages [94]. Recently, we established MSCs de‐
rived from bone marrow of adult Hexb-/- mice. The MSCs expressed cell-type specific mark‐
ers, including CD29, CD90 and CD54, but not CD45, and exhibited the ability to differentiate
into various cell types, including neuron-restricted precursor cells (NRPs) expressing N-
CAM carrying polysialic acid (PSA-NCAM). We produced a bicistronic retroviral vector
(MSV-modB) encoding for the modified human HEXB cDNAs (modB) causing six α-subunit
type amino acid substitutions as well as EGFP gene [75]. The gene products, modified HexB
(modB, a homodimer of the modified β-subunits) different from the wild-type HexB, can
recognize negatively charged artificial substrates and bind to GM2A to exhibit GM2-degrad‐
ing activity. We transduced the MSCs derived from Hexb-/- mice (SD MSCs) with the MSV-
modB, resulting in restoration of HexA-like activity and reduction of the accumulated GM2
and GlcNAc-oligosaccharides. The modB was also secreted from the transduced SD MSCs.
In addition, we performed intraventricular engraftment of the transduced SD MSCs express‐
ing modB into the brain of Hexb-/- mice. As a result, the injected transduced SD MSCs ex‐
pressing HexA-like activity and EGFP were observed in periventricular region of the brain
(Figure 1). Reduction of the immunoreactivity towards natural substrates including GM2
and GlcNAc-oligosaccharides were also observed around the periventricular region of
Hexb-/- mice brain (Figure 2). These results suggest that genetically modified MSCs can be
utilized as a brain-directed donor cells for ex vivo GT for LSDs involving neurological mani‐
festations, including Tay-Sachs and Sandhoff diseases.
Lee J-P. et al. demonstrated intracranial transplantation of neural stem cells (NSCs) delayed
onset, improved motor function, reduced GM2 storage and prolonged life span in the Hexb-/-
mice partly due to the cross correction effect of the Hex isozymes secreted from NSCs. Hu‐
man NSCs derived directly from the CNS and secondarily induced from embryonic stem
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(ES) cells also demonstrated a broad repertoire of potentially therapeutic actions, which are
expected to be applied for the treatment of neurodegenerative diseases [95]
5. Conclusion
A number of preclinical and therapeutic approaches for GM2 gangliosidoses, including stem
cell therapy, substrate deprivation therapy, gene therapy, and enzyme replacement therapy,
are being examined and evaluated with disease model mice, although there is no effective
therapy for treatment of the patients with GM2 gangliosidoses at present. However, accord‐
ing to the preclinical results obtained by using animal disease models, CNS-directed in vivo
gene therapy utilizing recombinant viral vectors and ex vivo gene therapy based on the
cross-correction by transduced autologous and heterologous stem cells are promising for de‐
velopment of novel therapies for LSDs associated with neurological abnormalities, including
GM2 gangliosidoses. Improvement of these GTs and their combination with other clinical
approaches will facilitate the development of efficient therapies for neurodegenerative dis‐
orders caused by neuroinflammation and gliosis.
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